VIAFLO 0.9% SODIUM CHLORIDE sodium chloride 450 mg/50 mL injection intravenous infusion bag Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

viaflo 0.9% sodium chloride sodium chloride 450 mg/50 ml injection intravenous infusion bag

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

POTASSIUM CHLORIDE 20 mmol in SODIUM CHLORIDE 0.9% 500 mL injection for intravenous infusion bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

potassium chloride 20 mmol in sodium chloride 0.9% 500 ml injection for intravenous infusion bottle

fresenius kabi australia pty ltd - potassium chloride, quantity: 3 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid - a source of water and to restore electrolyte balance as required by a patient's clinical condition, such as hypokalaemia

POTASSIUM CHLORIDE 10 mmol in SODIUM CHLORIDE 0.9% 500 mL injection for intravenous infusion bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

potassium chloride 10 mmol in sodium chloride 0.9% 500 ml injection for intravenous infusion bottle

fresenius kabi australia pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid - a source of water and to restore electrolyte balance as required by a patient's clinical condition, such as hypokalaemia

POTASSIUM CHLORIDE 20 mmol in SODIUM CHLORIDE 0.9% 1000 mL injection for intravenous infusion bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

potassium chloride 20 mmol in sodium chloride 0.9% 1000 ml injection for intravenous infusion bottle

fresenius kabi australia pty ltd - sodium chloride, quantity: 9 g/l; potassium chloride, quantity: 1.5 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid - a source of water and to restore electrolyte balance as required by a patient's clinical condition, such as hypokalaemia

POTASSIUM CHLORIDE 40 mmol in SODIUM CHLORIDE 0.9% 1000 mL injection for intravenous infusion bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

potassium chloride 40 mmol in sodium chloride 0.9% 1000 ml injection for intravenous infusion bottle

fresenius kabi australia pty ltd - potassium chloride, quantity: 3 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid - a source of water and to restore electrolyte balance as required by a patient's clinical condition, such as hypokalaemia

B. BRAUN GENTAMICIN gentamicin (as sulfate) 80 mg/80 mL injection, intravenous infusion, bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 80 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 240 mg/80 mL injection, intravenous infusion, bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 240 mg/80 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

B. BRAUN GENTAMICIN gentamicin (as sulfate) 360 mg/120 mL injection, intravenous infusion, bottle Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

b. braun gentamicin gentamicin (as sulfate) 360 mg/120 ml injection, intravenous infusion, bottle

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2531 mL bag Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2531 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

SMOFKABIVEN NTENSE amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2025 mL bag Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

smofkabiven ntense amino acid 6.5% with 0.7% electrolytes, lipids 2.9% & glucose 8.5 % emulsion for intravenous infusion 2025 ml bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium hydroxide; sodium oleate; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated